This study was conducted to examine the association of perfluoroalkyl substance（PFAS）exposure with gestational diabetes mellitus（GDM） risk and postpartum fasting blood glucose.We used a 1：2 matched case–control ...This study was conducted to examine the association of perfluoroalkyl substance（PFAS）exposure with gestational diabetes mellitus（GDM） risk and postpartum fasting blood glucose.We used a 1：2 matched case–control study with 84 GDM subjects and 168 healthy pregnant women from Beijing, China. The maternal blood was collected at 1–2 days before delivery, and eight linear isomers and fourteen branched isomers were determined in maternal serum.Logistic regression analyses were performed to evaluate the associations after adjusting for potential confounders. The median of the sum of levels of total PFASs was 4.24 ng/m L with a interquartile range（IQR） of 2.82–6.54 ng/m L. Although maternal PFAS exposure was not associated with risk of GDM, significant positive associations were observed between evaluated exposure to specific PFAS congeners and increasing blood glucose. The odds ratio（ORs） of the highest category of postpartum fasting blood glucose for perfluoro-1-metylheptylsulfonat（1 m-PFOS）, perfluoro-3/4-metylheptylsulfonat（3 m＋4 m-PFOS）, perfluoro-5-metylheptylsulfonat（5 m-PFOS）, and perfluorohexane sulfonate（PFHx S） were 2.03（95% CI： 1.09–3.77）, 1.93（95% CI：1.04–3.58）, 2.48（95% CI： 1.33–4.65）, and 2.26（95% CI： 1.21–4.21）, respectively, suggesting negative effects of maternal exposure to specific PFAS compounds on glucose metabolism.展开更多
目的分析门冬胰岛素联合地特胰岛素治疗妊娠合并糖尿病的临床效果。方法选择我院2017年3月至2018年3月收治的妊娠合并糖尿病患者78例为研究对象,采用随机数字法将其分为两组,各39例。门冬胰岛素组采用门冬胰岛素治疗,门冬+地特胰岛素组...目的分析门冬胰岛素联合地特胰岛素治疗妊娠合并糖尿病的临床效果。方法选择我院2017年3月至2018年3月收治的妊娠合并糖尿病患者78例为研究对象,采用随机数字法将其分为两组,各39例。门冬胰岛素组采用门冬胰岛素治疗,门冬+地特胰岛素组采用门冬胰岛素联合地特胰岛素治疗。比较两组治疗前、后的FBG、2 h PBG、Hb A1c及妊娠并发症发生情况。结果治疗前,两组的FBG、2 h PBG、Hb A1c比较,差异不具有统计学意义(P>0.05);治疗后,两组的FBG、2 h PBG、Hb A1c均降低,且门冬+地特胰岛素组低于门冬胰岛素组(P<0.05)。门冬+地特胰岛素组的妊娠并发症总发生率显著低于门冬胰岛素组(P<0.05)。结论门冬胰岛素联合地特胰岛素治疗妊娠合并糖尿病的临床效果显著,可推广应用。展开更多
基金supported by the National Natural Science Foundation of China(Nos.21537001and 21477030)the National Key Research and Development Program of China(No.2017YFC1600502)the Strategic Priority Research Program of the Chinese Academy of Sciences(No.XDB14010100)
文摘This study was conducted to examine the association of perfluoroalkyl substance（PFAS）exposure with gestational diabetes mellitus（GDM） risk and postpartum fasting blood glucose.We used a 1：2 matched case–control study with 84 GDM subjects and 168 healthy pregnant women from Beijing, China. The maternal blood was collected at 1–2 days before delivery, and eight linear isomers and fourteen branched isomers were determined in maternal serum.Logistic regression analyses were performed to evaluate the associations after adjusting for potential confounders. The median of the sum of levels of total PFASs was 4.24 ng/m L with a interquartile range（IQR） of 2.82–6.54 ng/m L. Although maternal PFAS exposure was not associated with risk of GDM, significant positive associations were observed between evaluated exposure to specific PFAS congeners and increasing blood glucose. The odds ratio（ORs） of the highest category of postpartum fasting blood glucose for perfluoro-1-metylheptylsulfonat（1 m-PFOS）, perfluoro-3/4-metylheptylsulfonat（3 m＋4 m-PFOS）, perfluoro-5-metylheptylsulfonat（5 m-PFOS）, and perfluorohexane sulfonate（PFHx S） were 2.03（95% CI： 1.09–3.77）, 1.93（95% CI：1.04–3.58）, 2.48（95% CI： 1.33–4.65）, and 2.26（95% CI： 1.21–4.21）, respectively, suggesting negative effects of maternal exposure to specific PFAS compounds on glucose metabolism.
文摘目的分析门冬胰岛素联合地特胰岛素治疗妊娠合并糖尿病的临床效果。方法选择我院2017年3月至2018年3月收治的妊娠合并糖尿病患者78例为研究对象,采用随机数字法将其分为两组,各39例。门冬胰岛素组采用门冬胰岛素治疗,门冬+地特胰岛素组采用门冬胰岛素联合地特胰岛素治疗。比较两组治疗前、后的FBG、2 h PBG、Hb A1c及妊娠并发症发生情况。结果治疗前,两组的FBG、2 h PBG、Hb A1c比较,差异不具有统计学意义(P>0.05);治疗后,两组的FBG、2 h PBG、Hb A1c均降低,且门冬+地特胰岛素组低于门冬胰岛素组(P<0.05)。门冬+地特胰岛素组的妊娠并发症总发生率显著低于门冬胰岛素组(P<0.05)。结论门冬胰岛素联合地特胰岛素治疗妊娠合并糖尿病的临床效果显著,可推广应用。
